The Buzz

ALACHUA – CTD Holdings, Inc., an Alachua based biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for its orphan drug product Trappsol® Cyclo™ in the treatment of Niemann-Pick Type C (NPC) disease. CTD will be initiating a Phase I study to investigate safety, tolerability, pharmacokinetic parameters and pharmacological effects of the intravenous administration of Trappsol® Cyclo™, CTD's hydroxypropyl beta cyclodextrin. Trappsol® Cyclo™ has Orphan Drug Designation in both the EU and the US.

“We are pleased to see Trappsol® Cyclo™ moving into its first formal clinical trial,” said N. Scott Fine, CTD Chairman and CEO. “With patients soon to be enrolled in the US, and with the Phase I/II Clinical Trial Application under review in the UK, this is an exciting time for our company and all stakeholders, and most importantly for the NPC families who are waiting for approved cyclodextrin-based treatments.”

Niemann-Pick Type C is a rare and fatal genetic disease that impacts primarily children but is increasingly diagnosed in older patients who may live with this disability for many years. NPC impacts the brain and major organs through abnormal accumulation of cholesterol in cells.

The randomized, double-blinded study will be centered at one site, UCSF Benioff Children's Hospital Oakland, and is expected to enroll 12 patients over the age of 18. It will examine two dosage levels of Trappsol® Cyclo™, 1500 mg/kgBW and 2500 mg/kgBW, administered intravenously, and will examine outcome measures on cholesterol synthesis and cholesterol storage in major organs, including the liver. “We were pleased by the level of cooperation and input from FDA as we finalized our study design,” said Dr. Sharon H. Hrynkow, CTD's Senior Vice President for Medical Affairs. More information on the study parameters will be posted to

“This approval is the culmination of years of work by many families and physicians along with CTD and other partners,” said Dr. Caroline Hastings, Pediatric Hematologist/Oncologist, UCSF Benioff Children's Hospital Oakland. “It is an honor to lead the formal clinical trial of IV administration of Trappsol® Cyclo™, the same cyclodextrin product used in named patient programs going back to 2009.”

#     #     #

Email editor@